SFX by Ex Libris Inc.

Title:	NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Source:	Nature [0028-0836] Duewell, P yr:2010

Basic

Full text

Full text available via Nature

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Moore, Kathryn J. "CD36 coordinates NLRP3 inflammasome activation by facilitating intracellular nucleation of soluble ligands into particulate ligands in sterile inflammation." Nature Immunology 14.8 (2013): 812-820.
description	2.	Hansson, Gran K. "The immune system in atherosclerosis." Nature Immunology 12.3 (2011): 204-212.
description	3.	Duewell, P. "Erratum: NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals (Nature (2010) 464 (1357-1361))." Nature 466.7306 (2010): 652-.
description	4.	Rabkin, Simon W. "The role of interleukin 18 in the pathogenesis of hypertension-induced vascular disease." Nature clinical practice: cardiovascular medicine 6.3 (2009): 192-9.
description	5.	Libby, P. "The molecular mechanisms of the thrombotic complications of atherosclerosis." Journal of internal medicine 263.5 (2008): 517-527.
description	6.	Lundberg, Anna M. "Innate immune signals in atherosclerosis." Clinical immunology 134.1 (2009): 5-24.
description	7.	Hansson, Göran K K. "The immune response in atherosclerosis: a double-edged sword." Nature reviews. Immunology 6.7 (2006): 508-519.
description	8.	Libby, P. "Immune effector mechanisms implicated in atherosclerosis: from mice to humans." Immunity 38.6 (2013): 1092-1104.
description	9.	Libby, P. "Progress and challenges in translating the biology of atherosclerosis." Nature 473.7347 (2011): 317-325.
description	10.	Hansson, Göran K K. "Inflammation, atherosclerosis, and coronary artery disease." The New England journal of medicine 352.16 (2005): 1685-1695.
description	11.	Schulz, C. "Platelets in atherosclerosis and thrombosis." Handbuch der experimentellen Pharmakologie / Handbook of Experimental Pharmacology 210.210 (2012): 111-133.
description	12.	Hernesniemi, Jussi A. "Interleukin 18 gene promoter polymorphism: a link between hypertension and pre-hospital sudden cardiac death: the Helsinki Sudden Death Study." European Heart Journal 30.23 (2009): 2939-2946.
description	13.	Taub, R. "Anti-inflammatory therapeutics for the treatment of atherosclerosis." Nature reviews. Drug discovery 10.5 (2011): 365-376.
description	14.	Fernandes-Alnemri T, Emad T. "Assembly, purification, and assay of the activity of the ASC pyroptosome." Methods Enzymol 442 (2008): 251-270.
description	15.	Björkbacka, H. "Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways." Nature medicine 10.4 (2004): 416-21.
description	16.	Glomset, J A A. "The pathogenesis of atherosclerosis (first of two parts)." New England Journal of Medicine, The 295.7 (1976): 369-77.
description	17.	Libby, P. "Intertwining of thrombosis and inflammation in atherosclerosis." Current opinion in hematology 14.1 (2006): 55-61.
description	18.	Smith, Smith E. "The biological paths of IL-1 family members IL-18 and IL-33." Journal of leukocyte biology 89.3 (2010): 383-392.
description	19.	Tschopp, J. "The inflammasomes: guardians of the body." Annual review of immunology 27.1 (2009): 229-65.
description	20.	Raines, W. "Thematic review series: The immune system and atherogenesis. Cytokines affecting endothelial and smooth muscle cells in vascular disease." Journal of lipid research 48.9 (2005): 1081-14.